Maximizing Outcome of Multiple Sclerosis Transplantation

NCT ID: NCT03342638

Last Updated: 2021-01-11

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 66 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-11-08
• Study Completion Date: 2019-10-09

Brief Summary

Randomized study of autologous un-manipulated peripheral blood hematopoietic stem cell transplant (HSCT) comparing two regimens: (1) cyclophosphamide and rabbit anti-thymoglobulin (rATG) versus (2) cyclophosphamide, rATG, and Intravenous Immunoglobulin (IVIg).

Detailed Description

Multiple sclerosis (MS) is at onset an immune-mediated demyelinating disease. In most cases, it starts as a relapsing-remitting disease with distinct attacks and no symptoms between flares. Over years or decades, virtually all cases transition into a progressive disease in which insidious and slow neurologic deterioration occurs with or without acute flares. Relapsing-remitting disease is often responsive to immune suppressive or modulating therapies, while immune based therapies are generally ineffective in patients with a progressive clinical course. This clinical course and response to immune suppression, as well as neuropathology and neuroimaging studies, suggest that disease progression is associated with axonal atrophy. Disability correlates better with measures of axonal atrophy than immune mediated demyelination. Therefore, immune based therapies, in order to be effective, need to be started early in the disease course while MS is predominantly an immune-mediated and inflammatory disease. While current immune based therapies delay disability, no intervention has been proven to prevent progressive disability.The investigators propose a randomized study of autologous unmanipulated peripheral blood hematopoietic stem cell transplant (HSCT) comparing two different conditioning regimens: (1) cyclophosphamide and rabbit anti-thymoglobulin (rATG) versus (2) cyclophosphamide, rATG, and Intravenous Immunoglobulin (IVIg).

Conditions

Multiple Sclerosis, Relapsing-Remitting

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Control Arm

Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) will be administered post-transplant.

Group Type: EXPERIMENTAL

Cyclophosphamide

Intervention Type: DRUG

Potent immunosuppressive agent; an alkylating agent

Mesna

Intervention Type: DRUG

Medication used to decrease the risk of hemorrhagic cystitis prophylaxis

rATG

Intervention Type: DRUG

A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells

Methylprednisolone

Intervention Type: DRUG

Steroid

G-CSF

Intervention Type: DRUG

Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream

Autologous Stem Cells

Intervention Type: BIOLOGICAL

Infusion of participant's own stem cells

IVIg Arm

Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. IVIg and G-CSF will be administered post-transplant.

Group Type: EXPERIMENTAL

Cyclophosphamide

Intervention Type: DRUG

Potent immunosuppressive agent; an alkylating agent

Mesna

Intervention Type: DRUG

Medication used to decrease the risk of hemorrhagic cystitis prophylaxis

rATG

Intervention Type: DRUG

A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells

Methylprednisolone

Intervention Type: DRUG

Steroid

G-CSF

Intervention Type: DRUG

Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream

IVIg

Intervention Type: BIOLOGICAL

Sterile, purified immunoglobulin G (IgG) products manufactured from pooled human plasma and typically contain more than 95% unmodified IgG, which has intact Fc-dependent effector functions and only trace amounts of immunoglobulin A (IgA) or immunoglobulin M (IgM).

Autologous Stem Cells

Intervention Type: BIOLOGICAL

Infusion of participant's own stem cells

Interventions

Cyclophosphamide

Potent immunosuppressive agent; an alkylating agent

Intervention Type: DRUG

Mesna

Medication used to decrease the risk of hemorrhagic cystitis prophylaxis

Intervention Type: DRUG

rATG

A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells

Intervention Type: DRUG

Methylprednisolone

Steroid

Intervention Type: DRUG

G-CSF

Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream

Intervention Type: DRUG

IVIg

Sterile, purified immunoglobulin G (IgG) products manufactured from pooled human plasma and typically contain more than 95% unmodified IgG, which has intact Fc-dependent effector functions and only trace amounts of immunoglobulin A (IgA) or immunoglobulin M (IgM).

Intervention Type: BIOLOGICAL

Autologous Stem Cells

Infusion of participant's own stem cells

Intervention Type: BIOLOGICAL

Other Intervention Names

Cytoxan; Neosar; Mesnex; Thymoglobulin; Solu-Medrol; Neupogen; Filgrastim; Granix; Zarxio; Gammagard; Carimune Nanofiltered (NF); Bivagam; Privigen

Eligibility Criteria

Inclusion Criteria

1. Age between 18-58 years

2. Diagnosis of MS using revised McDonald criteria of clinically definite MS (Appendix A)

3. An EDSS score of 2.0 to 6.0 (Appendix B).

4. An EDSS >6.0 may be included if still relapsing-remitting disease and at least two enhancing lesions on MRI within the last three months

5. Inflammatory disease despite treatment with standard disease modifying therapy (DMT) including at least 6 months of interferon or Copaxone. Inflammatory disease is defined based on either MRI (gadolinium enhancing lesion, new T2 lesion) or *steroid-treated clinical relapses (prescribed by a neurologist)

6. Minimum disease activity required:

1. Failed a first line DMT (Copaxone or Interferon), defined as two or more *steroid treated clinical relapses within the last 12 months. A clinical relapse may also be evidence of active inflammation on MRI (gadolinium enhancing lesion or new T2 lesion) in the last 12 months on two MRIs at least three months apart

2. Failed a second or third line MS Drug: Zinbryta (daclizumab), Aubagio (teriflunomide), Gilenya (fingolimod), Tecifidera (dimethyl fumarate), Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab) or IVIg, defined as one *steroid treated clinical relapse within the last 12 months or evidence of active inflammation on MRI (gadolinium enhancing lesion or new T2 lesion) in the last 12 months.

3. Cognitive dysfunction that prevents gainful employment, but competent to comply with treatment and informed consent

• A steroid-treated relapse will include a relapse that was severe enough to justify treatment but due to patient intolerance of steroids, they were offered but not used.

Exclusion Criteria

1. Any adult who is unable to consent (for adults who are cognitively impaired due to MS, consent may be obtained from the closest living relative or person who has power of attorney)

2. Individuals under the age of 18 or over the age of 58

3. Diagnosis of Primary Progressive MS, Secondary Progressive MS, or Clinically Isolated Syndrome (CIS)

4. Pregnant women (positive serum or urine human chorionic gonadotropin (HCG) test)

5. Women who are breastfeeding

6. Prisoners

7. Any illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive chemotherapy

8. Prior history of malignancy except localized basal cell, squamous skin cancer or carcinoma in situ of the cervix

9. Any prior chemotherapy or radiation therapy (except for cyclophosphamide used to treat MS disease)

10. History of sickle cell disease (SS), SC disease, coagulopathy, or if actively receiving anticoagulation therapy

11. History of insulin-dependent diabetes

12. Inability or unwillingness to pursue effective means of birth control from the time of evaluation for eligibility until 6 months post-transplant. Effective birth control is defined as (1) abstinence defined as refraining from all acts of vaginal intercourse, (2) consistent use of birth control pills, (3) injectable birth control methods (Depo-provera, Norplant), (4) tubal sterilization or male partner who has undergone vasectomy, (5) placement of an intrauterine device (IUD), or (6) with every act of intercourse, use of diaphragm with contraceptive jelly and/or use of condom with contraceptive foam

13. Failure to willingly accept or comprehend irreversible sterility as a side effect of therapy

14. Forced expiratory volume at one second (FEV1)/ forced vital capacity (FVC) < 60% of predicted after bronchodilator therapy (if necessary)

15. Diffusing capacity of the lungs for carbon monoxide (DLCO) < 60% of predicted

16. Resting left ventricular ejection fraction (LVEF) < 50 %

17. Bilirubin > 2.0 mg/dl

18. Serum creatinine > 2.0 mg/dl

19. Known hypersensitivity to mouse, rabbit, or E. Coli derived proteins or to iron compounds/medications

20. Presence of metallic objects implanted in the body that would preclude the ability of the patient to safely have MRI exams

21. Platelet count < 100,000/ul

22. White blood cell count (WBC) < 1,500 cells/mm3

23. Psychiatric illness, mental deficiency or cognitive dysfunction making compliance with treatment or informed consent impossible

24. Active infection except asymptomatic bacteriuria

25. Use of Tysabri (natalizumab) within the previous six months

26. Use of Gilenya (fingolimod) within the previous three months

27. Use of Tecfidera (dimethyl fumarate) within the previous three months

28. Use of Aubagio (teriflunomide) unless cleared from the body (plasma concentration <0.02mcg/ml) following elimination from the body with cholestyramine 8g three times a day for 11 days

29. Use of Lemtrada/Campath (alemtuzumab) within previous 12 months

30. Use of Rituxan (rituximab) or Ocrevus (ocrelizumab) within previous four months

31. Prior treatment with Novantrone (mitoxantrone)

32. Any hereditary neurological disease such as Charcot-Marie-Tooth disease (CMT), Spinocerebellar ataxia (SCA), or Parkinson's Disease

33. Severe or symptomatic cervical spinal stenosis unless surgically corrected

34. Myocardial infarction within last 12 months; if longer than 12 months, must pass dobutamine stress test and be cleared by cardiology

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 58 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Northwestern University

OTHER

Sponsor Role: lead

Responsible Party

Richard Burt, MD

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Richard Burt, MD

Role: PRINCIPAL_INVESTIGATOR

Northwestern University

Locations

Northwestern University

Chicago, Illinois, United States

Countries

United States

Provided Documents

Document Type: Study Protocol

View Document

Other Identifiers

DIAD.MOST.2017

Identifier Type: -

Identifier Source: org_study_id